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Evidence from rodent and in vitro models suggests that activation of PPAR-γ by thiazolidinediones (TZDs) causes increased bone
marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes,
providinganopportunitytodeterminewhetherPPAR-γ activationalsoimpactsboneinhumans.Inaddition,sincetype2diabetes
is associated with higher fracture risk, an understanding of the clinical impact of TZDs on bone is needed to guide fracture
prevention eﬀorts in this population. This review summarizes current ﬁndings regarding type 2 diabetes and increased fracture
risk and then considers the available evidence regarding TZD use and bone metabolism in humans.
Copyright © 2006 Ann V. Schwartz. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Thiazolidinediones (TZDs) are an eﬀective treatment for di-
abetes that increase insulin sensitivity through activation of
peroxisome proliferator-activated receptor (PPAR)-γ.A c t i -
vationofPPAR-γ byTZDsmayalsocauseanincreaseinbone
marrow adiposity and a decrease in osteoblastogenesis, re-
sulting in reduced bone formation [1]. TZDs are reported to
c a u s eb o n el o s si ns o m e[ 1–4], but not all [5], rodent mod-
els. However, little information is available on the eﬀects of
TZDs on bone in humans.
The increased use of TZD treatment is taking place in the
context of growing evidence that type 2 diabetes (T2DM) is
associated with a higher risk of fracture. If TZDs cause bone
loss in humans, use of TZD treatments could add to this in-
creased fracture risk. Reports on TZD use and fracture risk
are not currently available, in part because widespread use of
TZDs is relatively recent. Some limited clinical and observa-
tional studies have addressed the impact of TZD use on bone
turnover and bone density. This review presents current ev-
idence that type 2 diabetes is associated with higher fracture
risk and then considers the available evidence regarding the
impact of TZD use on bone in humans.
TYPE 2 DIABETES IS ASSOCIATED WITH AN INCREASED
RISK OF FRACTURE
Nonvertebralfractures
Until relatively recently, type 2 diabetes was not considered
a risk factor for fracture. Type 2 diabetes is associated with
increased weight which provides protection from most frac-
tures. In 1980, a large retrospective study using Mayo Clinic
records reported that diabetes was not associated with in-
creased risk of fracture except at the ankle [6]. However, re-
cent studies have reported that those with type 2 diabetes
are at higher risk for hip (Table 1)[ 7–14], proximal humerus
[9, 10], foot [9, 15], and all nonvertebral fractures combined
(Table 2)[ 9, 10, 13, 16].
As shown in Table 1, the age-adjusted eﬀect estimates for
the relative risk of hip fracture associated with type 2 dia-
betes range from 1.1t o5 .8i no l d e rw o m e na n d1 .0t o7 .7i n
older men. Diabetes is generally associated with being over-
weight and with higher bone mineral density (BMD). Thus,
with adjustment for body size and/or BMD in these studies,
the relative risks are somewhat higher.
Impairedglucosemetabolism
Two studies have also considered increased fracture risk in
those with impaired glucose metabolism. In both studies,
thosewithimpairedglucosemetabolismaswellasthosewith
diabetes had higher BMD than those with normal glucose
homeostasis. In the Rotterdam Study, impaired glucose tol-
erance, compared with normal glucose tolerance, was associ-
ated with a reduced risk of nonvertebral fracture, adjusted
for BMD and body size (HR = 0.80; 95% CI: 0.63–1.00)
[13]. Results from the Health, Aging, and Body Composition
Study (Health ABC) showed a modest increase in nonverte-
bral fracture risk in those with impaired fasting glucose but2 PPAR Research
Table 1: Age-adjusted relative risk of hip fracture for older adults with type 2 diabetes.
Study Gender Age RR 95% CI
Cardiovascular Disease in Norwegian Women 35–49 5.8 2.2–15.7
Countries (1993) [7] Men 35–49 7.72 .4–24.5
Nord-Trondelag Health Survey (1999) [8]
Women 50–74 1.71 .1–2.7
Men 50–74 1.00 .4–2.6
Study of Osteoporotic Fractures (2001) [9]W o m e n ≥ 65 1.51 .1–2.0
Iowa Women’s Health Study (2001) [10] Women 55–69 1.81 .2–2.4
Hispanic EPESE (2002) [11]
Men and
≥ 65 1.6∗ 1.0–2.4
Women
Tromso Study (2005) [12]
Women 25–98 1.71 .0–3.0
Men 25–98 1.4 0.5–4.0
Rotterdam Study (2005) [13]
Women ≥ 55 1.10 .7–1.6
Men ≥ 55 1.40 .7–2.8
Malmo Preventive Project (2005) [14]
Women 28–58 4.11 .8–9.3
Men 27–61 7.74 .4–13.7
∗Adjusted for age, gender, current smoking, BMI, history of stroke.
Table 2: Adjusted relative risk of nonvertebral fracture with type 2 diabetes.
Study Gender Age RR 95% CI
Study of Osteoporotic Fractures (2001) [9]W o m e n ≥ 65 1.31 .1–1.5
Iowa Women’s Health Study (2001) [10] Women 55–69
Insulin treated — — 1.51 .1–1.9
Not insulin treated — — 1.1 1.0–1.3
Tromso Study (2005) [12]
Women 25–98 1.10 .7–1.7
Men 25–98 1.20 .6–2.5
Health ABC Study (2005) [16]
Men and 70–79 1.61 .1–2.5
Women
Rotterdam Study (2005) [13]
Men and
≥ 55 1.31 .0–1.8
Women
conﬁdenceintervals werewide(adjusted HR =1.34; 95% CI:
0.67–2.67) [16].
Vertebralfractures
Based on ﬁndings from three studies that identiﬁed vertebral
fractures from spine radiographs, it appears that the risk of
vertebralfracturesmaynotbe increasedwithtype 2diabetes.
Diabetic women aged 50 years and older in a Canadian study
had no increase in prevalent vertebral fractures (OR = 0.92;
95% CI: 0.67–1.25) [17]. Additionally, there were no diﬀer-
encesinprevalentvertebralfracturebydiabetesstatusamong
older women with low bone density enrolled in the Fracture
Intervention Trial [18]. For incident vertebral fractures, the
study of osteoporotic fractures (SOF) reported no increased
risk in women with type 2 diabetes over an average of 3.7
years (OR = 1.1; 95% CI: 0.69–1.83) [9].
Reasonsforincreasedfracturerisk:
fallsandbonestrength
The reasons for increased fracture risk with type 2 diabetes
are not well understood. T2DM have average or higher BMD
even after adjustment for body size [19–21]. However, dia-
betic bone may be more fragile for a given BMD [22]. We
have also found evidence in the Health ABC Study that older
white women with diabetes were losing bone at the hip more
rapidlythanthosewithoutdiabetes,eventhoughthediabetic
womenhadhigherBMDatbaseline[23].Theincreasedbone
loss was partly accounted for by greater weight loss in the di-
abetic, compared with nondiabetic, women. Weight loss cor-
relates with bone loss and increased bone turnover in older
adults [24, 25]. The reasons for increased weight loss with
diabetes in this cohort are not known. However, a study in
the Pima Indians reported that weight loss after the onset of
diabetes was found in those who were not treated with hypo-
glycemic medications [26].
T2DM is also associated with an increased risk of falls
[27–30]. More frequent falls are known to increase fracture
risk, and this probably accounts for at least some of the
higher fracture risk with diabetes. However, adjustment for
frequency of falls has not fully explained the association be-
tween diabetes and fracture in previous studies [9, 16]. It is
likely that other factors such as decreased bone strength and
bone loss also contribute to increased fracture risk [31].Ann V. Schwartz 3
Similar to well-known ﬁndings in the broader popula-
tion, lower BMD predicts fracture in older adults with di-
abetes. Among the older diabetic adults in the Health ABC
Study, those who experienced a fracture had an average total
hip BMD at baseline that was 15% lower than those with-
out fracture [16]. Thus, although type 2 diabetes is associ-
ated with higher BMD, loss of BMD would still be expected
to increase fracture risk.
It has been suggested that TZD use may explain some of
the increased fracture risk observed in older adults with type
2 diabetes [32]. However, the data for studies reporting in-
creased fracture risk with diabetes were generally acquired
before use of TZDs for diabetes treatment. Troglitazone was
available in the USA from 1997 to 2000 when it was removed
fromthemarketbecauseofrarecasesoffatalliverdisease.Pi-
oglitazone and rosiglitazone were ﬁrst available for prescrip-
tion in the USA in 1999. In 2001, TZDs accounted for 17%
of market share for oral hypoglycemic medications [33]. It is
unlikely that TZD use accounts for the currently published
reports of an increased fracture risk with type 2 diabetes.
TZDS AND BONE LOSS
Evidencefromrodentandinvitromodels
Several lines of evidence from rodent and in vitro models
pointtothepossibilitythattreatmentwithTZDscausesbone
loss. The results of these investigations are reviewed in ac-
companying articles in this special issue and are only men-
tioned brieﬂy here. In rodent models, Rzonca et al [1]a n d
others [2] have reported bone loss with rosiglitazone treat-
ment in mouse models, and Sottile et al [3] found bone loss
in ovariectomized rats treated with rosiglitazone although
no eﬀect was seen in intact animals. Jennermann et al re-
ported decreased BMD with pioglitazone treatment in rats
[4]. However, Tornvig et al reported that troglitazone treat-
ment did not cause bone loss in mice [5].
In vitro studies have shown that PPAR-γ activation with
TZDs promotes the diﬀerentiation of precursor cells into
adipocytes and inhibits their diﬀerentiation into osteoblasts
[34, 35]. These eﬀects of PPAR-γ activation are not necessar-
ily bound together. Use of ligands other than rosiglitazone to
activate PPAR-γ has been shown to promote only the proad-
ipogenic or only the antiosteoblastogenic pathways [36, 37].
TheseresultssuggestthatitmaybepossibletoidentifyPPAR-
γ activators that promote insulin sensitivity without inhibit-
ing osteoblastogenesis [38].
Evidencefromclinicalstudies
The current clinical studies of TZD use and bone are limited
in size and study design and have not produced consistent
results.
Boneturnover
A study in 33 type 2 diabetic patients found that troglitazone
treatment (400mg per day) for four weeks reduced markers
of bone turnover, including formation and resorption mark-
ers, by a modest amount (7–13%) [39]. This may reﬂect a
direct eﬀect of troglitazone on bone metabolism, or it may
be an indirect result of improved glycemic control on bone.
The impact of hyperglycemia on bone is not well studied but
some reports indicate that improved glycemic control is as-
sociatedwithareductioninboneturnover[40].Inthisstudy
of troglitazone, baseline mean A1C was 8.4%, and was essen-
tially unchanged after 4 weeks of treatment. Mean FPG was
reduced, although the change was not statistically signiﬁcant
with 4 weeks of treatment, and this may at least partly ac-
count for the reduction in bone turnover with troglitazone
use.
In another study of troglitazone use, Watanabe et al
treated 25 patients (14 women) with type 2 diabetes for 12
months with 400mg per day. Similar to the previous re-
port, this study found that levels of urine type 1 collagen
N-telopeptide and serum bone alkaline phosphatase were
modestly reduced after the ﬁrst month of treatment by 14%
and 9%, respectively. However, both markers had returned
to baseline levels after 12 months of troglitazone treatment
[41].
Bonedensity
Watanabe et al also reported that, for the patient group as a
whole, lumbar spine BMD Z-scores were not changed after
12 months of troglitazone. When patients were divided into
those who did (responders; N = 17) or did not (nonrespon-
ders; N = 8) experience a reduction in leptin levels during
treatment,theleptinrespondershadlessbonelosscompared
with the nonresponders. Bone loss in the nonresponders was
similar to a group of nondiabetic controls with hypercholes-
terolemia.TherespondersalsohadgreaterreductionsinA1C
compared with the nonresponders. The BMD results in the
subgroups deﬁned by leptin changes could be due to direct
troglitazone eﬀects, improved glycemic control, or chance.
Using data from the Health, Aging, and Body Composi-
tion Study (Health ABC), an observational cohort study, we
assessed TZD use and bone loss over four years among par-
ticipants with type 2 diabetes [42]. Participants were white
andblack,physicallyable,menandwomen,aged70–79years
at baseline [23]. We analyzed changes in whole body, lumbar
spine (derived from whole body), and hip BMD.
There were 666 diabetic participants in Health ABC, and
69 of them reported TZD use at an annual visit, including
troglitazone(N = 22),pioglitazone(N = 30),and/orrosigli-
tazone (N = 31). In repeated measures models adjusted for
potential confounders associated with TZD use and BMD,
each year of TZD use was associated with greater bone loss at
the whole body (additional loss of −0.61% per year; 95% CI:
−1.02, −0.21% per year), lumbar spine (−1.23% per year;
95% CI: −2.06, −0.40% per year), and trochanter (−0.65%
per year; 95% CI: −1.18, −0.12% per year) in women, but
not men, with diabetes.
The average whole body bone loss among diabetic
women who were not using a TZD in Health ABC was 0.4%
per year. TZD use appears to increase whole body bone loss4 PPAR Research
by a factor of 2.5. Bone loss is a potent predictor of fracture
risk, suggesting that TZD use may be associated with a mea-
surable eﬀect on skeletal health.
For women who used TZDs continuously, these results
predict an additional whole body bone loss of 3% over ﬁve
years. A cross-sectional diﬀerence of 1SD in whole body
BMD, or a diﬀerence of about 10% in BMD, corresponds
to an increased hip fracture risk of 60% [43]. Thus, long-
term use of TZDs by diabetic women may add substantially
to their fracture risk. This burden is in addition to any in-
creased risk of fracture associated with diabetes.
In contrast to these observational ﬁndings in Health
ABC, the study of one year of troglitazone administration
found that bone loss at the lumbar spine was not increased
beyond changes expected with age [41]. However, the re-
sults of these two studies may not be inconsistent. The
Health ABC study found increased bone loss with TZD use
only in women. The troglitazone study included only 14
women, and this group may have been too small to de-
tect increased bone loss conﬁned to women. It is also pos-
sible that troglitazone has a diﬀerent eﬀect than the other
TZDs on bone and that the results from the Health ABC
Study are driven by eﬀects of rosiglitazone and/or pioglita-
zone rather than troglitazone. In rodent models the one re-
ported study with troglitazone did not ﬁnd bone loss, al-
though troglitazone did induce adipogenesis in bone mar-
row [5]. In contrast, rosiglitazone and pioglitazone have pro-
duced bone loss as well as adipogenesis in rodent mod-
els [1–4]. Diﬀerent eﬀects of these medications on bone
metabolism would be consistent with reports that the re-
sults of PPAR-γ activation depend on the particular ligand
[36].
LimitationsofDXAscans
The standard approach for measuring changes in BMD is
dual X-ray absorptiometry (DXA), employed in both of the
clinical studies discussed here. However, there are inherent
limitations of DXA scans for studying changes in bone den-
sity associated with TZD use. Increases in body weight may
cause artifactual changes in BMD while increases in bone
marrow fat may cause artifactual decreases in BMD as mea-
sured by DXA.
To derive BMD values, DXA must assume values for soft
tissue mass over- and underlying bone. These soft-tissue val-
uesarederivedfromthesurroundingsofttissue,andahigher
proportion of fat in the surrounding soft tissue results in an
over-estimation of the true value of BMD [44]. With weight
gain, the fat composition in the diﬀerent areas of soft tis-
sue may change at diﬀerent rates, introducing artifactual in-
creases or decreases in measured BMD changes [45]. The ef-
fectof weightchangeonDXAmeasurementsmaydependon
the particular scanner and software version used [46]. Thus,
the increased weight and body fat associated with TZD use
could tend to artiﬁcially increase or decrease any observed
bone loss.
Bone marrow is included in the DXA scan of bone tis-
sue and an increase in bone marrow fat may artiﬁcially lower
the DXA measurement, the opposite eﬀectof weight gain de-
scribed above [47]. The eﬀect of TZD on bone marrow com-
position has not been addressed in human studies. In rodent
models, TZD use has been reported to increase [1], and to
have no eﬀect on [2], bone marrow fat. If TZD use causes an
increase in bone marrow fat in humans, this could artiﬁcially
lower bone density as measured by DXA.
FUTURE DIRECTIONS
Given the evidence of bone loss in rodent models, it would
be prudent to understand the impact of TZD treatment on
bone in humans, especially as these medications are being
considered for prevention as well as treatment of diabetes.
A carefully designed clinical trial is needed at this juncture
to test whether TZD use causes bone loss. New research will
particularly need to address the limitations of DXA scans in
the context of a treatment that changes body composition
and may alter bone marrow composition. Now that TZD use
has become more prevalent, data from larger observational
studies with fracture outcomes could be used to address the
association between TZD use and fracture risk.
CONCLUSION
Clinical studies to date on TZD and bone have been limited
by small size and relatively short duration of TZD use. In ad-
dition, studies to date have either been observational or have
included only a treatment group. Separate clinical data are
not available on the two TZDs currently in use, rosiglitazone
and pioglitazone. Thus, we do not know if the bone loss ob-
served with TZD administration in some rodent models is
also occurring in type 2 diabetic patients treated with TZDs.
A well-designed clinical trial, planned speciﬁcally to examine
the impact of TZD use on bone density, would clarify this is-
sue.Becauseolderadultswithtype2diabetesareatincreased
risk of fracture, further study of TZDs is needed to assess the
possible risk of bone loss. At the same time, clinical studies
of the eﬀect of TZDs on bone could provide valuable insights
into the role of PPAR-γ in bone metabolism.
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